Tzu Chi Medical Journal
Volume 23, Issue 4 , Pages 111-114 , December 2011

C-reactive protein positively correlates with metabolic syndrome in coronary artery disease patients

  • Bang-Gee Hsu

      Affiliations

    • Department of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • School of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • Jen-Che Hsieh

      Affiliations

    • Department of Cardiology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • ,
  • Yu-Chih Chen

      Affiliations

    • Department of Cardiology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • ,
  • Ji-Hung Wang

      Affiliations

    • School of Medicine, Tzu Chi University, Hualien, Taiwan
    • Department of Cardiology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Cardiology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan. Tel.: +886 3 8561825; fax: +886 3 8577161.

Received 4 July 2011 ,Revised 18 August 2011 ,Accepted 12 October 2011.

References 

  1. Vahdat K, Jafari SM, Pazoki R, Nabipour I. Concurrent increased high sensitivity C-reactive protein and chronic infections are associated with coronary artery disease: a population-based study. Indian J Med Sci. 2007;61:135–143
  2. Deveci E, Yesil M, Akinci B, Yesil S, Postaci N, Arikan E, et al. Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol. 2009;32:32–36
  3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  4. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  5. Anuurad E, Tracy RP, Pearson TA, Beckett L, Berglund L. Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans. Am J Cardiol. 2009;103:523–527
  6. Solymoss BC, Bourassa MG, Marcil M, Levesque S, Varga S, Campeau L. Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations. Coron Artery Dis. 2009;20:1–8
  7. Arcari A, Zito F, Di Castelnuovo A, De Curtis A, Dirckx C, Arnout J, et al. C reactive protein and its determinants in healthy men and women from European regions at different risk of coronary disease: the IMMIDIET Project. J Thromb Haemost. 2008;6:436–443
  8. Hsu BG, Chen YC, Lee RP, Lee CC, Lee CJ, Wang JH. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J. 2010;74:327–331
  9. Alberti KG, Zimmet PZ, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480
  10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553
  11. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol. 2003;92:35i–42i
  12. Anuurad E, Chiem A, Pearson TA, Berglund L. Metabolic syndrome components in African-Americans and European-American patients and its relation to coronary artery disease. Am J Cardiol. 2007;100:830–834
  13. Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, Sung KC, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009;160:165–172
  14. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–197
  15. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B. C reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005;167:1139–1148
  16. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20:182–189
  17. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1–11
  18. Calabrò P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol. 2009;31:79–94
  19. Rasouli M, Kiasari AM. Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. Clin Biochem. 2006;39:971–977
  20. Poledne R, Lorenzová A, Stávek P, Valenta Z, Hubácek J, Suchánek P, et al. Proinflammatory status, genetics and atherosclerosis. Physiol Res. 2009;58(Suppl. 2):S111–S118
  21. Tintera J, Harantová P, Suchánek P, Dvoráková A, Adamová M, Hájek M, et al. Quantification of intra-abdominal fat during controlled weight reduction: assessment using the water-suppressed breath-hold MRI technique. Physiol Res. 2004;53:229–234
  22. Lapice E, Maione S, Patti L, Cipriano P, Rivellese AA, Riccardi G, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32:1734–1736
  23. Kao TW, Lu IS, Liao KC, Lai HY, Loh CH, Kuo HK. Associations between body mass index and serum levels of C-reactive protein. S Afr Med J. 2009;99:326–330
  24. Wu CK, Yang CY, Lin JW, Hsieh HJ, Chiu FC, Chen JJ, et al. The relationship among central obesity, systemic inflammation, and left ventricular diastolic dysfunction as determined by structural equation modeling. Obesity. 2011 Mar 10;[Epub ahead of print]
  25. Aronson D, Goldberg A, Roguin A, Petcherski S, Rimer D, Gruberg L, et al. Effect of obesity on the relationship between plasma C-reactive protein and coronary artery stenosis in patients with stable angina. Atherosclerosis. 2006;185:137–142
  26. Genser B, Grammer TB, Stojakovic T, Siekmeier R, März W. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther. 2008;46:497–510
  27. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol. 2006;26:977–986
  28. Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus. 2005;14:794–797
  29. Palmas W, Ma S, Psaty B, Goff DC, Darwin C, Barr RG. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens. 2007;20:233–241

PII: S1016-3190(11)00101-7

doi: 10.1016/j.tcmj.2011.10.006

Tzu Chi Medical Journal
Volume 23, Issue 4 , Pages 111-114 , December 2011

Article Tools